Broadly Neutralizing Antibodies Derived from the Earliest COVID-19 Convalescents Protect Mice from SARS-CoV-2 Variants Challenge

Investigators developed six human monoclonal antibodies (mAbs) from two elite convalescents in Wuhan and showed that these mAbs recognize diverse epitopes on the receptor binding domain and can inhibit the infection of SARS-CoV-2 original strain and variants.